nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—Cytochrome P450 3A4 Inhibitors—Cyclosporine—psoriasis	0.39	1	CiPCiCtD
Aprepitant—colon cancer—Dexamethasone—psoriasis	0.125	0.366	CpDpCtD
Aprepitant—colon cancer—Betamethasone—psoriasis	0.125	0.366	CpDpCtD
Aprepitant—breast cancer—Dexamethasone—psoriasis	0.0459	0.134	CpDpCtD
Aprepitant—breast cancer—Betamethasone—psoriasis	0.0459	0.134	CpDpCtD
Aprepitant—CYP3A5—Beclomethasone—psoriasis	0.0197	0.106	CbGbCtD
Aprepitant—CYP1A2—Clobetasol propionate—psoriasis	0.0193	0.105	CbGbCtD
Aprepitant—CYP1A2—Methoxsalen—psoriasis	0.0101	0.0549	CbGbCtD
Aprepitant—CYP3A7—Hydrocortisone—psoriasis	0.00838	0.0453	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.00838	0.0453	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.00791	0.0428	CbGbCtD
Aprepitant—CYP3A7—Cyclosporine—psoriasis	0.00791	0.0428	CbGbCtD
Aprepitant—CYP3A5—Mycophenolate mofetil—psoriasis	0.00783	0.0424	CbGbCtD
Aprepitant—CYP2C19—Cholecalciferol—psoriasis	0.00729	0.0394	CbGbCtD
Aprepitant—CYP3A4—Calcitriol—psoriasis	0.00684	0.037	CbGbCtD
Aprepitant—CYP3A5—Hydrocortisone—psoriasis	0.00628	0.034	CbGbCtD
Aprepitant—CYP2C9—Cholecalciferol—psoriasis	0.00606	0.0328	CbGbCtD
Aprepitant—CYP3A5—Cyclosporine—psoriasis	0.00594	0.0321	CbGbCtD
Aprepitant—CYP3A4—Methoxsalen—psoriasis	0.00532	0.0288	CbGbCtD
Aprepitant—CYP3A7—Dexamethasone—psoriasis	0.00521	0.0282	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00521	0.0282	CbGbCtD
Aprepitant—CYP2C19—Prednisone—psoriasis	0.00505	0.0273	CbGbCtD
Aprepitant—CYP2C19—Cyclosporine—psoriasis	0.00479	0.0259	CbGbCtD
Aprepitant—CYP2C9—Cyclosporine—psoriasis	0.00398	0.0215	CbGbCtD
Aprepitant—CYP3A5—Dexamethasone—psoriasis	0.00391	0.0212	CbGbCtD
Aprepitant—CYP3A4—Cholecalciferol—psoriasis	0.00352	0.0191	CbGbCtD
Aprepitant—CYP2C19—Dexamethasone—psoriasis	0.00315	0.0171	CbGbCtD
Aprepitant—CYP3A4—Mycophenolate mofetil—psoriasis	0.00305	0.0165	CbGbCtD
Aprepitant—CYP3A4—Triamcinolone—psoriasis	0.00305	0.0165	CbGbCtD
Aprepitant—CYP2C9—Dexamethasone—psoriasis	0.00262	0.0142	CbGbCtD
Aprepitant—CYP3A4—Betamethasone—psoriasis	0.00262	0.0142	CbGbCtD
Aprepitant—CYP3A4—Prednisolone—psoriasis	0.00259	0.014	CbGbCtD
Aprepitant—CYP3A4—Hydrocortisone—psoriasis	0.00245	0.0133	CbGbCtD
Aprepitant—CYP3A4—Prednisone—psoriasis	0.00244	0.0132	CbGbCtD
Aprepitant—CYP3A4—Cyclosporine—psoriasis	0.00231	0.0125	CbGbCtD
Aprepitant—CYP3A4—Dexamethasone—psoriasis	0.00152	0.00825	CbGbCtD
Aprepitant—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.000509	0.0463	CbGpPWpGaD
Aprepitant—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000459	0.0417	CbGpPWpGaD
Aprepitant—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000418	0.0381	CbGpPWpGaD
Aprepitant—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000368	0.0335	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000356	0.0323	CbGpPWpGaD
Aprepitant—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000284	0.0259	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—CCL20—psoriasis	0.000275	0.025	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—HCAR2—psoriasis	0.000271	0.0246	CbGpPWpGaD
Aprepitant—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000259	0.0236	CbGpPWpGaD
Aprepitant—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000222	0.0202	CbGpPWpGaD
Aprepitant—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000211	0.0192	CbGpPWpGaD
Aprepitant—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000209	0.019	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000185	0.0168	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000174	0.0158	CbGpPWpGaD
Aprepitant—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000171	0.0156	CbGpPWpGaD
Aprepitant—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000171	0.0156	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000157	0.0143	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—HCAR2—psoriasis	0.000153	0.0139	CbGpPWpGaD
Aprepitant—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000153	0.0139	CbGpPWpGaD
Aprepitant—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000151	0.0137	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—CCL20—psoriasis	0.000141	0.0128	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—HCAR2—psoriasis	0.000139	0.0126	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000134	0.0122	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—HCAR2—psoriasis	0.000132	0.012	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL13—psoriasis	0.000124	0.0113	CbGpPWpGaD
Aprepitant—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000124	0.0113	CbGpPWpGaD
Aprepitant—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000118	0.0107	CbGpPWpGaD
Aprepitant—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000117	0.0106	CbGpPWpGaD
Aprepitant—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000108	0.00979	CbGpPWpGaD
Aprepitant—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000106	0.00967	CbGpPWpGaD
Aprepitant—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	9.58e-05	0.00871	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—IL4—psoriasis	9.46e-05	0.0086	CbGpPWpGaD
Aprepitant—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	9.2e-05	0.00837	CbGpPWpGaD
Aprepitant—CYP3A7—Biological oxidations—CYP2S1—psoriasis	9.1e-05	0.00828	CbGpPWpGaD
Aprepitant—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	9.08e-05	0.00826	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	9.02e-05	0.0082	CbGpPWpGaD
Aprepitant—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	8.98e-05	0.00816	CbGpPWpGaD
Aprepitant—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	8.73e-05	0.00794	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—HCAR2—psoriasis	8.21e-05	0.00747	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—LEP—psoriasis	8e-05	0.00727	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CCL20—psoriasis	7.95e-05	0.00723	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL10—psoriasis	7.78e-05	0.00707	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	7.74e-05	0.00704	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—ICAM1—psoriasis	7.51e-05	0.00683	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—HCAR2—psoriasis	7.47e-05	0.0068	CbGpPWpGaD
Aprepitant—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	7.46e-05	0.00679	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—NOS2—psoriasis	7.45e-05	0.00678	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—CXCL8—psoriasis	7.44e-05	0.00676	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CCL20—psoriasis	7.22e-05	0.00656	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TAGAP—psoriasis	7.12e-05	0.00647	CbGpPWpGaD
Aprepitant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	7.1e-05	0.00646	CbGpPWpGaD
Aprepitant—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	7.01e-05	0.00637	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CCL20—psoriasis	6.87e-05	0.00625	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—HCAR2—psoriasis	6.79e-05	0.00617	CbGpPWpGaD
Aprepitant—CYP3A5—Biological oxidations—CYP2S1—psoriasis	6.58e-05	0.00598	CbGpPWpGaD
Aprepitant—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	6.49e-05	0.0059	CbGpPWpGaD
Aprepitant—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	5.76e-05	0.00524	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—IFNG—psoriasis	5.72e-05	0.0052	CbGpPWpGaD
Aprepitant—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	5.68e-05	0.00517	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—CXCL8—psoriasis	5.32e-05	0.00483	CbGpPWpGaD
Aprepitant—CYP2C19—Biological oxidations—CYP2S1—psoriasis	5.09e-05	0.00463	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	5.02e-05	0.00456	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.99e-05	0.00454	CbGpPWpGaD
Aprepitant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.95e-05	0.0045	CbGpPWpGaD
Aprepitant—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	4.93e-05	0.00449	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—CYP2S1—psoriasis	4.64e-05	0.00422	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	4.57e-05	0.00416	CbGpPWpGaD
Aprepitant—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	4.51e-05	0.0041	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	4.42e-05	0.00402	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCL20—psoriasis	4.26e-05	0.00388	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—CXCL8—psoriasis	4.25e-05	0.00387	CbGpPWpGaD
Aprepitant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.23e-05	0.00384	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HCAR2—psoriasis	4.01e-05	0.00365	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—CYP2S1—psoriasis	3.96e-05	0.0036	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—JUN—psoriasis	3.95e-05	0.00359	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	3.91e-05	0.00355	CbGpPWpGaD
Aprepitant—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	3.9e-05	0.00355	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CCL20—psoriasis	3.88e-05	0.00353	CbGpPWpGaD
Aprepitant—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	3.84e-05	0.00349	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—NFKB1—psoriasis	3.81e-05	0.00346	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—CXCL8—psoriasis	3.8e-05	0.00345	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	3.78e-05	0.00344	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	3.78e-05	0.00344	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—TNF—psoriasis	3.7e-05	0.00337	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—CXCL8—psoriasis	3.63e-05	0.0033	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CCL20—psoriasis	3.53e-05	0.00321	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TAGAP—psoriasis	3.48e-05	0.00316	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—VEGFA—psoriasis	3.45e-05	0.00314	CbGpPWpGaD
Aprepitant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.45e-05	0.00314	CbGpPWpGaD
Aprepitant—CYP1A2—Tryptophan metabolism—CAT—psoriasis	3.42e-05	0.00311	CbGpPWpGaD
Aprepitant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	3.26e-05	0.00297	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—TP53—psoriasis	3.26e-05	0.00297	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—CYP2S1—psoriasis	3.06e-05	0.00278	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	3.02e-05	0.00274	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—IL6—psoriasis	2.99e-05	0.00272	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—TNF—psoriasis	2.96e-05	0.00269	CbGpPWpGaD
Aprepitant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.95e-05	0.00268	CbGpPWpGaD
Aprepitant—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	2.93e-05	0.00267	CbGpPWpGaD
Aprepitant—CYP3A4—Tryptophan metabolism—CAT—psoriasis	2.64e-05	0.0024	CbGpPWpGaD
Aprepitant—Body temperature increased—Cyclosporine—psoriasis	2.58e-05	0.000355	CcSEcCtD
Aprepitant—Anxiety—Dexamethasone—psoriasis	2.57e-05	0.000355	CcSEcCtD
Aprepitant—Anxiety—Betamethasone—psoriasis	2.57e-05	0.000355	CcSEcCtD
Aprepitant—Vomiting—Mycophenolic acid—psoriasis	2.56e-05	0.000353	CcSEcCtD
Aprepitant—Discomfort—Betamethasone—psoriasis	2.55e-05	0.000352	CcSEcCtD
Aprepitant—Discomfort—Dexamethasone—psoriasis	2.55e-05	0.000352	CcSEcCtD
Aprepitant—Dyspepsia—Hydrocortisone—psoriasis	2.55e-05	0.000352	CcSEcCtD
Aprepitant—Rash—Mycophenolic acid—psoriasis	2.54e-05	0.00035	CcSEcCtD
Aprepitant—Dermatitis—Mycophenolic acid—psoriasis	2.54e-05	0.00035	CcSEcCtD
Aprepitant—Pain—Prednisolone—psoriasis	2.54e-05	0.00035	CcSEcCtD
Aprepitant—Urticaria—Mycophenolate mofetil—psoriasis	2.53e-05	0.000348	CcSEcCtD
Aprepitant—Headache—Mycophenolic acid—psoriasis	2.53e-05	0.000348	CcSEcCtD
Aprepitant—Decreased appetite—Hydrocortisone—psoriasis	2.52e-05	0.000347	CcSEcCtD
Aprepitant—Pharyngitis—Methotrexate—psoriasis	2.52e-05	0.000347	CcSEcCtD
Aprepitant—Abdominal pain—Mycophenolate mofetil—psoriasis	2.52e-05	0.000347	CcSEcCtD
Aprepitant—Body temperature increased—Mycophenolate mofetil—psoriasis	2.52e-05	0.000347	CcSEcCtD
Aprepitant—Urinary tract disorder—Methotrexate—psoriasis	2.51e-05	0.000345	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Hydrocortisone—psoriasis	2.5e-05	0.000345	CcSEcCtD
Aprepitant—Fatigue—Hydrocortisone—psoriasis	2.5e-05	0.000344	CcSEcCtD
Aprepitant—Urethral disorder—Methotrexate—psoriasis	2.49e-05	0.000343	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Triamcinolone—psoriasis	2.49e-05	0.000343	CcSEcCtD
Aprepitant—Pain—Hydrocortisone—psoriasis	2.48e-05	0.000342	CcSEcCtD
Aprepitant—Oedema—Betamethasone—psoriasis	2.48e-05	0.000341	CcSEcCtD
Aprepitant—Oedema—Dexamethasone—psoriasis	2.48e-05	0.000341	CcSEcCtD
Aprepitant—Anaphylactic shock—Betamethasone—psoriasis	2.48e-05	0.000341	CcSEcCtD
Aprepitant—Anaphylactic shock—Dexamethasone—psoriasis	2.48e-05	0.000341	CcSEcCtD
Aprepitant—Insomnia—Triamcinolone—psoriasis	2.47e-05	0.00034	CcSEcCtD
Aprepitant—Infection—Betamethasone—psoriasis	2.46e-05	0.000339	CcSEcCtD
Aprepitant—Infection—Dexamethasone—psoriasis	2.46e-05	0.000339	CcSEcCtD
Aprepitant—Ill-defined disorder—Prednisone—psoriasis	2.45e-05	0.000338	CcSEcCtD
Aprepitant—Paraesthesia—Triamcinolone—psoriasis	2.45e-05	0.000338	CcSEcCtD
Aprepitant—Feeling abnormal—Prednisolone—psoriasis	2.45e-05	0.000337	CcSEcCtD
Aprepitant—Anaemia—Prednisone—psoriasis	2.44e-05	0.000337	CcSEcCtD
Aprepitant—Shock—Betamethasone—psoriasis	2.44e-05	0.000336	CcSEcCtD
Aprepitant—Shock—Dexamethasone—psoriasis	2.44e-05	0.000336	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.44e-05	0.00222	CbGpPWpGaD
Aprepitant—Dyspnoea—Triamcinolone—psoriasis	2.43e-05	0.000335	CcSEcCtD
Aprepitant—Nervous system disorder—Betamethasone—psoriasis	2.43e-05	0.000335	CcSEcCtD
Aprepitant—Nervous system disorder—Dexamethasone—psoriasis	2.43e-05	0.000335	CcSEcCtD
Aprepitant—Thrombocytopenia—Dexamethasone—psoriasis	2.42e-05	0.000334	CcSEcCtD
Aprepitant—Thrombocytopenia—Betamethasone—psoriasis	2.42e-05	0.000334	CcSEcCtD
Aprepitant—Tachycardia—Dexamethasone—psoriasis	2.42e-05	0.000333	CcSEcCtD
Aprepitant—Tachycardia—Betamethasone—psoriasis	2.42e-05	0.000333	CcSEcCtD
Aprepitant—Angioedema—Prednisone—psoriasis	2.41e-05	0.000333	CcSEcCtD
Aprepitant—Hypersensitivity—Cyclosporine—psoriasis	2.4e-05	0.000331	CcSEcCtD
Aprepitant—Dyspepsia—Triamcinolone—psoriasis	2.4e-05	0.000331	CcSEcCtD
Aprepitant—Erythema multiforme—Methotrexate—psoriasis	2.4e-05	0.000331	CcSEcCtD
Aprepitant—Nausea—Mycophenolic acid—psoriasis	2.39e-05	0.00033	CcSEcCtD
Aprepitant—Hyperhidrosis—Dexamethasone—psoriasis	2.39e-05	0.00033	CcSEcCtD
Aprepitant—Hyperhidrosis—Betamethasone—psoriasis	2.39e-05	0.00033	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL6—psoriasis	2.39e-05	0.00217	CbGpPWpGaD
Aprepitant—Feeling abnormal—Hydrocortisone—psoriasis	2.39e-05	0.000329	CcSEcCtD
Aprepitant—Malaise—Prednisone—psoriasis	2.38e-05	0.000328	CcSEcCtD
Aprepitant—Eye disorder—Methotrexate—psoriasis	2.37e-05	0.000327	CcSEcCtD
Aprepitant—Gastrointestinal pain—Hydrocortisone—psoriasis	2.37e-05	0.000327	CcSEcCtD
Aprepitant—Syncope—Prednisone—psoriasis	2.37e-05	0.000327	CcSEcCtD
Aprepitant—Tinnitus—Methotrexate—psoriasis	2.37e-05	0.000326	CcSEcCtD
Aprepitant—Anorexia—Betamethasone—psoriasis	2.36e-05	0.000325	CcSEcCtD
Aprepitant—Anorexia—Dexamethasone—psoriasis	2.36e-05	0.000325	CcSEcCtD
Aprepitant—Urticaria—Prednisolone—psoriasis	2.36e-05	0.000325	CcSEcCtD
Aprepitant—Cardiac disorder—Methotrexate—psoriasis	2.35e-05	0.000324	CcSEcCtD
Aprepitant—Fatigue—Triamcinolone—psoriasis	2.35e-05	0.000324	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—SOCS1—psoriasis	2.35e-05	0.00214	CbGpPWpGaD
Aprepitant—Hypersensitivity—Mycophenolate mofetil—psoriasis	2.34e-05	0.000323	CcSEcCtD
Aprepitant—Asthenia—Cyclosporine—psoriasis	2.34e-05	0.000322	CcSEcCtD
Aprepitant—Pain—Triamcinolone—psoriasis	2.33e-05	0.000322	CcSEcCtD
Aprepitant—Loss of consciousness—Prednisone—psoriasis	2.32e-05	0.00032	CcSEcCtD
Aprepitant—Hypotension—Dexamethasone—psoriasis	2.31e-05	0.000319	CcSEcCtD
Aprepitant—Hypotension—Betamethasone—psoriasis	2.31e-05	0.000319	CcSEcCtD
Aprepitant—Pruritus—Cyclosporine—psoriasis	2.31e-05	0.000318	CcSEcCtD
Aprepitant—Urticaria—Hydrocortisone—psoriasis	2.3e-05	0.000317	CcSEcCtD
Aprepitant—Angiopathy—Methotrexate—psoriasis	2.3e-05	0.000317	CcSEcCtD
Aprepitant—Immune system disorder—Methotrexate—psoriasis	2.29e-05	0.000316	CcSEcCtD
Aprepitant—Abdominal pain—Hydrocortisone—psoriasis	2.29e-05	0.000316	CcSEcCtD
Aprepitant—Body temperature increased—Hydrocortisone—psoriasis	2.29e-05	0.000316	CcSEcCtD
Aprepitant—Convulsion—Prednisone—psoriasis	2.29e-05	0.000316	CcSEcCtD
Aprepitant—Mediastinal disorder—Methotrexate—psoriasis	2.29e-05	0.000315	CcSEcCtD
Aprepitant—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	2.29e-05	0.00208	CbGpPWpGaD
Aprepitant—Asthenia—Mycophenolate mofetil—psoriasis	2.28e-05	0.000315	CcSEcCtD
Aprepitant—Hypertension—Prednisone—psoriasis	2.28e-05	0.000314	CcSEcCtD
Aprepitant—Chills—Methotrexate—psoriasis	2.28e-05	0.000314	CcSEcCtD
Aprepitant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.27e-05	0.00207	CbGpPWpGaD
Aprepitant—Musculoskeletal discomfort—Dexamethasone—psoriasis	2.26e-05	0.000311	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Betamethasone—psoriasis	2.26e-05	0.000311	CcSEcCtD
Aprepitant—Pruritus—Mycophenolate mofetil—psoriasis	2.25e-05	0.00031	CcSEcCtD
Aprepitant—Myalgia—Prednisone—psoriasis	2.25e-05	0.00031	CcSEcCtD
Aprepitant—Arthralgia—Prednisone—psoriasis	2.25e-05	0.00031	CcSEcCtD
Aprepitant—Feeling abnormal—Triamcinolone—psoriasis	2.25e-05	0.00031	CcSEcCtD
Aprepitant—Anxiety—Prednisone—psoriasis	2.24e-05	0.000309	CcSEcCtD
Aprepitant—Alopecia—Methotrexate—psoriasis	2.24e-05	0.000309	CcSEcCtD
Aprepitant—Insomnia—Dexamethasone—psoriasis	2.24e-05	0.000309	CcSEcCtD
Aprepitant—Insomnia—Betamethasone—psoriasis	2.24e-05	0.000309	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—TYK2—psoriasis	2.24e-05	0.00204	CbGpPWpGaD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	2.23e-05	0.000308	CcSEcCtD
Aprepitant—Diarrhoea—Cyclosporine—psoriasis	2.23e-05	0.000308	CcSEcCtD
Aprepitant—Paraesthesia—Dexamethasone—psoriasis	2.22e-05	0.000306	CcSEcCtD
Aprepitant—Paraesthesia—Betamethasone—psoriasis	2.22e-05	0.000306	CcSEcCtD
Aprepitant—Discomfort—Prednisone—psoriasis	2.22e-05	0.000306	CcSEcCtD
Aprepitant—Mental disorder—Methotrexate—psoriasis	2.22e-05	0.000306	CcSEcCtD
Aprepitant—Malnutrition—Methotrexate—psoriasis	2.21e-05	0.000304	CcSEcCtD
Aprepitant—Erythema—Methotrexate—psoriasis	2.21e-05	0.000304	CcSEcCtD
Aprepitant—Hypersensitivity—Prednisolone—psoriasis	2.19e-05	0.000301	CcSEcCtD
Aprepitant—Dyspepsia—Betamethasone—psoriasis	2.18e-05	0.0003	CcSEcCtD
Aprepitant—Dyspepsia—Dexamethasone—psoriasis	2.18e-05	0.0003	CcSEcCtD
Aprepitant—Diarrhoea—Mycophenolate mofetil—psoriasis	2.18e-05	0.0003	CcSEcCtD
Aprepitant—Urticaria—Triamcinolone—psoriasis	2.17e-05	0.000299	CcSEcCtD
Aprepitant—Dysgeusia—Methotrexate—psoriasis	2.16e-05	0.000298	CcSEcCtD
Aprepitant—Body temperature increased—Triamcinolone—psoriasis	2.16e-05	0.000297	CcSEcCtD
Aprepitant—Dizziness—Cyclosporine—psoriasis	2.16e-05	0.000297	CcSEcCtD
Aprepitant—Anaphylactic shock—Prednisone—psoriasis	2.16e-05	0.000297	CcSEcCtD
Aprepitant—Oedema—Prednisone—psoriasis	2.16e-05	0.000297	CcSEcCtD
Aprepitant—Decreased appetite—Betamethasone—psoriasis	2.15e-05	0.000297	CcSEcCtD
Aprepitant—Decreased appetite—Dexamethasone—psoriasis	2.15e-05	0.000297	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—CXCL8—psoriasis	2.15e-05	0.00195	CbGpPWpGaD
Aprepitant—Infection—Prednisone—psoriasis	2.14e-05	0.000295	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Betamethasone—psoriasis	2.14e-05	0.000295	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Dexamethasone—psoriasis	2.14e-05	0.000295	CcSEcCtD
Aprepitant—Back pain—Methotrexate—psoriasis	2.14e-05	0.000294	CcSEcCtD
Aprepitant—Hypersensitivity—Hydrocortisone—psoriasis	2.14e-05	0.000294	CcSEcCtD
Aprepitant—Fatigue—Betamethasone—psoriasis	2.14e-05	0.000294	CcSEcCtD
Aprepitant—Fatigue—Dexamethasone—psoriasis	2.14e-05	0.000294	CcSEcCtD
Aprepitant—Shock—Prednisone—psoriasis	2.12e-05	0.000292	CcSEcCtD
Aprepitant—Pain—Dexamethasone—psoriasis	2.12e-05	0.000292	CcSEcCtD
Aprepitant—Pain—Betamethasone—psoriasis	2.12e-05	0.000292	CcSEcCtD
Aprepitant—Nervous system disorder—Prednisone—psoriasis	2.11e-05	0.000291	CcSEcCtD
Aprepitant—Tachycardia—Prednisone—psoriasis	2.1e-05	0.00029	CcSEcCtD
Aprepitant—Dizziness—Mycophenolate mofetil—psoriasis	2.1e-05	0.00029	CcSEcCtD
Aprepitant—Skin disorder—Prednisone—psoriasis	2.09e-05	0.000289	CcSEcCtD
Aprepitant—Hyperhidrosis—Prednisone—psoriasis	2.08e-05	0.000287	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—CCL20—psoriasis	2.08e-05	0.00189	CbGpPWpGaD
Aprepitant—Asthenia—Hydrocortisone—psoriasis	2.08e-05	0.000287	CcSEcCtD
Aprepitant—Vomiting—Cyclosporine—psoriasis	2.07e-05	0.000286	CcSEcCtD
Aprepitant—Rash—Cyclosporine—psoriasis	2.06e-05	0.000283	CcSEcCtD
Aprepitant—Anorexia—Prednisone—psoriasis	2.06e-05	0.000283	CcSEcCtD
Aprepitant—Dermatitis—Cyclosporine—psoriasis	2.05e-05	0.000283	CcSEcCtD
Aprepitant—Pruritus—Hydrocortisone—psoriasis	2.05e-05	0.000283	CcSEcCtD
Aprepitant—Ill-defined disorder—Methotrexate—psoriasis	2.05e-05	0.000282	CcSEcCtD
Aprepitant—Headache—Cyclosporine—psoriasis	2.04e-05	0.000282	CcSEcCtD
Aprepitant—Anaemia—Methotrexate—psoriasis	2.04e-05	0.000281	CcSEcCtD
Aprepitant—Feeling abnormal—Dexamethasone—psoriasis	2.04e-05	0.000281	CcSEcCtD
Aprepitant—Feeling abnormal—Betamethasone—psoriasis	2.04e-05	0.000281	CcSEcCtD
Aprepitant—Gastrointestinal pain—Betamethasone—psoriasis	2.03e-05	0.000279	CcSEcCtD
Aprepitant—Gastrointestinal pain—Dexamethasone—psoriasis	2.03e-05	0.000279	CcSEcCtD
Aprepitant—Vomiting—Mycophenolate mofetil—psoriasis	2.02e-05	0.000279	CcSEcCtD
Aprepitant—Hypersensitivity—Triamcinolone—psoriasis	2.01e-05	0.000277	CcSEcCtD
Aprepitant—Rash—Mycophenolate mofetil—psoriasis	2.01e-05	0.000276	CcSEcCtD
Aprepitant—Dermatitis—Mycophenolate mofetil—psoriasis	2e-05	0.000276	CcSEcCtD
Aprepitant—Headache—Mycophenolate mofetil—psoriasis	1.99e-05	0.000275	CcSEcCtD
Aprepitant—Malaise—Methotrexate—psoriasis	1.99e-05	0.000274	CcSEcCtD
Aprepitant—Diarrhoea—Hydrocortisone—psoriasis	1.98e-05	0.000273	CcSEcCtD
Aprepitant—Urticaria—Dexamethasone—psoriasis	1.97e-05	0.000271	CcSEcCtD
Aprepitant—Urticaria—Betamethasone—psoriasis	1.97e-05	0.000271	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Prednisone—psoriasis	1.96e-05	0.000271	CcSEcCtD
Aprepitant—Dizziness—Prednisolone—psoriasis	1.96e-05	0.00027	CcSEcCtD
Aprepitant—Asthenia—Triamcinolone—psoriasis	1.96e-05	0.00027	CcSEcCtD
Aprepitant—Body temperature increased—Betamethasone—psoriasis	1.96e-05	0.00027	CcSEcCtD
Aprepitant—Abdominal pain—Betamethasone—psoriasis	1.96e-05	0.00027	CcSEcCtD
Aprepitant—Abdominal pain—Dexamethasone—psoriasis	1.96e-05	0.00027	CcSEcCtD
Aprepitant—Body temperature increased—Dexamethasone—psoriasis	1.96e-05	0.00027	CcSEcCtD
Aprepitant—Insomnia—Prednisone—psoriasis	1.95e-05	0.000269	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—CXCL8—psoriasis	1.95e-05	0.00177	CbGpPWpGaD
Aprepitant—Nausea—Cyclosporine—psoriasis	1.94e-05	0.000267	CcSEcCtD
Aprepitant—Paraesthesia—Prednisone—psoriasis	1.94e-05	0.000267	CcSEcCtD
Aprepitant—Pruritus—Triamcinolone—psoriasis	1.93e-05	0.000266	CcSEcCtD
Aprepitant—Cough—Methotrexate—psoriasis	1.93e-05	0.000266	CcSEcCtD
Aprepitant—Dizziness—Hydrocortisone—psoriasis	1.92e-05	0.000264	CcSEcCtD
Aprepitant—Convulsion—Methotrexate—psoriasis	1.91e-05	0.000264	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	1.9e-05	0.00173	CbGpPWpGaD
Aprepitant—Dyspepsia—Prednisone—psoriasis	1.9e-05	0.000262	CcSEcCtD
Aprepitant—Nausea—Mycophenolate mofetil—psoriasis	1.89e-05	0.00026	CcSEcCtD
Aprepitant—Arthralgia—Methotrexate—psoriasis	1.88e-05	0.000259	CcSEcCtD
Aprepitant—Myalgia—Methotrexate—psoriasis	1.88e-05	0.000259	CcSEcCtD
Aprepitant—Chest pain—Methotrexate—psoriasis	1.88e-05	0.000259	CcSEcCtD
Aprepitant—Decreased appetite—Prednisone—psoriasis	1.87e-05	0.000258	CcSEcCtD
Aprepitant—Rash—Prednisolone—psoriasis	1.87e-05	0.000258	CcSEcCtD
Aprepitant—Dermatitis—Prednisolone—psoriasis	1.87e-05	0.000258	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	1.87e-05	0.000257	CcSEcCtD
Aprepitant—Fatigue—Prednisone—psoriasis	1.86e-05	0.000256	CcSEcCtD
Aprepitant—Headache—Prednisolone—psoriasis	1.86e-05	0.000256	CcSEcCtD
Aprepitant—Discomfort—Methotrexate—psoriasis	1.86e-05	0.000256	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—CXCL8—psoriasis	1.86e-05	0.00169	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.85e-05	0.00168	CbGpPWpGaD
Aprepitant—Constipation—Prednisone—psoriasis	1.84e-05	0.000254	CcSEcCtD
Aprepitant—Vomiting—Hydrocortisone—psoriasis	1.84e-05	0.000254	CcSEcCtD
Aprepitant—CYP3A7—Metabolism—NDUFA5—psoriasis	1.83e-05	0.00166	CbGpPWpGaD
Aprepitant—Rash—Hydrocortisone—psoriasis	1.83e-05	0.000252	CcSEcCtD
Aprepitant—Dermatitis—Hydrocortisone—psoriasis	1.83e-05	0.000252	CcSEcCtD
Aprepitant—Confusional state—Methotrexate—psoriasis	1.82e-05	0.00025	CcSEcCtD
Aprepitant—Headache—Hydrocortisone—psoriasis	1.82e-05	0.00025	CcSEcCtD
Aprepitant—Dizziness—Triamcinolone—psoriasis	1.8e-05	0.000249	CcSEcCtD
Aprepitant—Anaphylactic shock—Methotrexate—psoriasis	1.8e-05	0.000248	CcSEcCtD
Aprepitant—Infection—Methotrexate—psoriasis	1.79e-05	0.000247	CcSEcCtD
Aprepitant—Feeling abnormal—Prednisone—psoriasis	1.78e-05	0.000245	CcSEcCtD
Aprepitant—Asthenia—Betamethasone—psoriasis	1.78e-05	0.000245	CcSEcCtD
Aprepitant—Asthenia—Dexamethasone—psoriasis	1.78e-05	0.000245	CcSEcCtD
Aprepitant—Nervous system disorder—Methotrexate—psoriasis	1.77e-05	0.000244	CcSEcCtD
Aprepitant—Thrombocytopenia—Methotrexate—psoriasis	1.76e-05	0.000243	CcSEcCtD
Aprepitant—Gastrointestinal pain—Prednisone—psoriasis	1.76e-05	0.000243	CcSEcCtD
Aprepitant—Nausea—Prednisolone—psoriasis	1.76e-05	0.000243	CcSEcCtD
Aprepitant—Pruritus—Dexamethasone—psoriasis	1.75e-05	0.000241	CcSEcCtD
Aprepitant—Pruritus—Betamethasone—psoriasis	1.75e-05	0.000241	CcSEcCtD
Aprepitant—Skin disorder—Methotrexate—psoriasis	1.75e-05	0.000241	CcSEcCtD
Aprepitant—Hyperhidrosis—Methotrexate—psoriasis	1.74e-05	0.00024	CcSEcCtD
Aprepitant—Vomiting—Triamcinolone—psoriasis	1.74e-05	0.000239	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—LEP—psoriasis	1.73e-05	0.00158	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—APOE—psoriasis	1.73e-05	0.00158	CbGpPWpGaD
Aprepitant—Nausea—Hydrocortisone—psoriasis	1.72e-05	0.000237	CcSEcCtD
Aprepitant—Rash—Triamcinolone—psoriasis	1.72e-05	0.000237	CcSEcCtD
Aprepitant—Dermatitis—Triamcinolone—psoriasis	1.72e-05	0.000237	CcSEcCtD
Aprepitant—Anorexia—Methotrexate—psoriasis	1.72e-05	0.000237	CcSEcCtD
Aprepitant—Urticaria—Prednisone—psoriasis	1.71e-05	0.000236	CcSEcCtD
Aprepitant—Headache—Triamcinolone—psoriasis	1.71e-05	0.000236	CcSEcCtD
Aprepitant—Abdominal pain—Prednisone—psoriasis	1.7e-05	0.000235	CcSEcCtD
Aprepitant—Body temperature increased—Prednisone—psoriasis	1.7e-05	0.000235	CcSEcCtD
Aprepitant—Diarrhoea—Dexamethasone—psoriasis	1.69e-05	0.000234	CcSEcCtD
Aprepitant—Diarrhoea—Betamethasone—psoriasis	1.69e-05	0.000234	CcSEcCtD
Aprepitant—Hypotension—Methotrexate—psoriasis	1.68e-05	0.000232	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Methotrexate—psoriasis	1.64e-05	0.000226	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	1.64e-05	0.00149	CbGpPWpGaD
Aprepitant—Dizziness—Betamethasone—psoriasis	1.64e-05	0.000226	CcSEcCtD
Aprepitant—Dizziness—Dexamethasone—psoriasis	1.64e-05	0.000226	CcSEcCtD
Aprepitant—Insomnia—Methotrexate—psoriasis	1.63e-05	0.000225	CcSEcCtD
Aprepitant—Nausea—Triamcinolone—psoriasis	1.62e-05	0.000223	CcSEcCtD
Aprepitant—Paraesthesia—Methotrexate—psoriasis	1.62e-05	0.000223	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—NFKBIA—psoriasis	1.61e-05	0.00147	CbGpPWpGaD
Aprepitant—Dyspnoea—Methotrexate—psoriasis	1.61e-05	0.000221	CcSEcCtD
Aprepitant—Somnolence—Methotrexate—psoriasis	1.6e-05	0.000221	CcSEcCtD
Aprepitant—Hypersensitivity—Prednisone—psoriasis	1.59e-05	0.000219	CcSEcCtD
Aprepitant—Dyspepsia—Methotrexate—psoriasis	1.59e-05	0.000219	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	1.58e-05	0.00144	CbGpPWpGaD
Aprepitant—Vomiting—Dexamethasone—psoriasis	1.57e-05	0.000217	CcSEcCtD
Aprepitant—Vomiting—Betamethasone—psoriasis	1.57e-05	0.000217	CcSEcCtD
Aprepitant—Decreased appetite—Methotrexate—psoriasis	1.57e-05	0.000216	CcSEcCtD
Aprepitant—Rash—Betamethasone—psoriasis	1.56e-05	0.000215	CcSEcCtD
Aprepitant—Rash—Dexamethasone—psoriasis	1.56e-05	0.000215	CcSEcCtD
Aprepitant—Dermatitis—Dexamethasone—psoriasis	1.56e-05	0.000215	CcSEcCtD
Aprepitant—Dermatitis—Betamethasone—psoriasis	1.56e-05	0.000215	CcSEcCtD
Aprepitant—CYP3A7—Metabolism—CYP2S1—psoriasis	1.56e-05	0.00142	CbGpPWpGaD
Aprepitant—Gastrointestinal disorder—Methotrexate—psoriasis	1.56e-05	0.000214	CcSEcCtD
Aprepitant—Fatigue—Methotrexate—psoriasis	1.55e-05	0.000214	CcSEcCtD
Aprepitant—Headache—Dexamethasone—psoriasis	1.55e-05	0.000214	CcSEcCtD
Aprepitant—Headache—Betamethasone—psoriasis	1.55e-05	0.000214	CcSEcCtD
Aprepitant—Asthenia—Prednisone—psoriasis	1.55e-05	0.000213	CcSEcCtD
Aprepitant—Pain—Methotrexate—psoriasis	1.54e-05	0.000212	CcSEcCtD
Aprepitant—Pruritus—Prednisone—psoriasis	1.53e-05	0.00021	CcSEcCtD
Aprepitant—Feeling abnormal—Methotrexate—psoriasis	1.49e-05	0.000205	CcSEcCtD
Aprepitant—Diarrhoea—Prednisone—psoriasis	1.48e-05	0.000203	CcSEcCtD
Aprepitant—Gastrointestinal pain—Methotrexate—psoriasis	1.47e-05	0.000203	CcSEcCtD
Aprepitant—Nausea—Dexamethasone—psoriasis	1.47e-05	0.000203	CcSEcCtD
Aprepitant—Nausea—Betamethasone—psoriasis	1.47e-05	0.000203	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	1.43e-05	0.0013	CbGpPWpGaD
Aprepitant—Urticaria—Methotrexate—psoriasis	1.43e-05	0.000197	CcSEcCtD
Aprepitant—Dizziness—Prednisone—psoriasis	1.43e-05	0.000197	CcSEcCtD
Aprepitant—Body temperature increased—Methotrexate—psoriasis	1.42e-05	0.000196	CcSEcCtD
Aprepitant—Abdominal pain—Methotrexate—psoriasis	1.42e-05	0.000196	CcSEcCtD
Aprepitant—Vomiting—Prednisone—psoriasis	1.37e-05	0.000189	CcSEcCtD
Aprepitant—Rash—Prednisone—psoriasis	1.36e-05	0.000187	CcSEcCtD
Aprepitant—Dermatitis—Prednisone—psoriasis	1.36e-05	0.000187	CcSEcCtD
Aprepitant—Headache—Prednisone—psoriasis	1.35e-05	0.000186	CcSEcCtD
Aprepitant—Hypersensitivity—Methotrexate—psoriasis	1.33e-05	0.000183	CcSEcCtD
Aprepitant—CYP3A5—Metabolism—NDUFA5—psoriasis	1.32e-05	0.0012	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TYK2—psoriasis	1.32e-05	0.0012	CbGpPWpGaD
Aprepitant—Asthenia—Methotrexate—psoriasis	1.29e-05	0.000178	CcSEcCtD
Aprepitant—Nausea—Prednisone—psoriasis	1.28e-05	0.000177	CcSEcCtD
Aprepitant—Pruritus—Methotrexate—psoriasis	1.28e-05	0.000176	CcSEcCtD
Aprepitant—Diarrhoea—Methotrexate—psoriasis	1.23e-05	0.00017	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	1.23e-05	0.00112	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	1.23e-05	0.00112	CbGpPWpGaD
Aprepitant—Dizziness—Methotrexate—psoriasis	1.19e-05	0.000164	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CXCL8—psoriasis	1.15e-05	0.00105	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SOCS1—psoriasis	1.15e-05	0.00104	CbGpPWpGaD
Aprepitant—Vomiting—Methotrexate—psoriasis	1.15e-05	0.000158	CcSEcCtD
Aprepitant—Rash—Methotrexate—psoriasis	1.14e-05	0.000157	CcSEcCtD
Aprepitant—Dermatitis—Methotrexate—psoriasis	1.14e-05	0.000156	CcSEcCtD
Aprepitant—Headache—Methotrexate—psoriasis	1.13e-05	0.000156	CcSEcCtD
Aprepitant—CYP3A5—Metabolism—CYP2S1—psoriasis	1.13e-05	0.00102	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—IL6—psoriasis	1.1e-05	0.000996	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—TYK2—psoriasis	1.09e-05	0.000994	CbGpPWpGaD
Aprepitant—Nausea—Methotrexate—psoriasis	1.07e-05	0.000148	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—JUN—psoriasis	1.07e-05	0.000973	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CXCL8—psoriasis	1.05e-05	0.000953	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—NFKB1—psoriasis	1.03e-05	0.000937	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NDUFA5—psoriasis	1.02e-05	0.00093	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.54e-06	0.000867	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CXCL8—psoriasis	9.52e-06	0.000866	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—VEGFA—psoriasis	9.35e-06	0.00085	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NDUFA5—psoriasis	9.33e-06	0.000848	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—STAT3—psoriasis	9.26e-06	0.000842	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP2S1—psoriasis	8.7e-06	0.000791	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	8.7e-06	0.000791	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—LEP—psoriasis	8.46e-06	0.00077	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—APOE—psoriasis	8.46e-06	0.00077	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NDUFA5—psoriasis	7.97e-06	0.000725	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP2S1—psoriasis	7.93e-06	0.000721	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NFKBIA—psoriasis	7.89e-06	0.000717	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CARM1—psoriasis	7.6e-06	0.000691	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.43e-06	0.000676	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TP53—psoriasis	7.07e-06	0.000643	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP2S1—psoriasis	6.78e-06	0.000616	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL6—psoriasis	6.47e-06	0.000588	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TYK2—psoriasis	6.46e-06	0.000587	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NDUFA5—psoriasis	6.15e-06	0.000559	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCL8—psoriasis	5.62e-06	0.000511	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CARM1—psoriasis	5.5e-06	0.0005	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL6—psoriasis	5.35e-06	0.000486	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP2S1—psoriasis	5.23e-06	0.000476	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—JUN—psoriasis	5.23e-06	0.000475	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NFKB1—psoriasis	5.03e-06	0.000458	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CAT—psoriasis	4.68e-06	0.000425	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—VEGFA—psoriasis	4.57e-06	0.000415	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.56e-06	0.000415	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—STAT3—psoriasis	4.52e-06	0.000411	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CARM1—psoriasis	4.25e-06	0.000386	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.16e-06	0.000378	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.97e-06	0.000361	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CARM1—psoriasis	3.87e-06	0.000352	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—APOE—psoriasis	3.63e-06	0.00033	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.62e-06	0.000329	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.55e-06	0.000323	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TP53—psoriasis	3.45e-06	0.000314	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CAT—psoriasis	3.38e-06	0.000307	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CARM1—psoriasis	3.31e-06	0.000301	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PPARG—psoriasis	3.16e-06	0.000288	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL6—psoriasis	3.16e-06	0.000287	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.09e-06	0.000281	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—APOE—psoriasis	2.63e-06	0.000239	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CAT—psoriasis	2.61e-06	0.000238	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CARM1—psoriasis	2.55e-06	0.000232	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CAT—psoriasis	2.38e-06	0.000217	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PPARG—psoriasis	2.29e-06	0.000208	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CAT—psoriasis	2.04e-06	0.000185	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—APOE—psoriasis	2.03e-06	0.000185	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—APOE—psoriasis	1.85e-06	0.000168	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PPARG—psoriasis	1.77e-06	0.000161	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PPARG—psoriasis	1.61e-06	0.000147	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—APOE—psoriasis	1.58e-06	0.000144	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CAT—psoriasis	1.57e-06	0.000143	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PPARG—psoriasis	1.38e-06	0.000125	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—APOE—psoriasis	1.22e-06	0.000111	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PPARG—psoriasis	1.06e-06	9.67e-05	CbGpPWpGaD
